Introduction
============

Epithelial ovarian cancer (EOC) remains the most lethal type of gynecologic malignancy in postmenopausal women in industrialized countries ([@b1-ol-0-0-5969]). Comprising a heterogeneous group of malignant tumors, EOC presents with distinct clinicopathological and biological characteristics. The majority (\~75%) of all incidences of ovarian cancer are classified as high-grade serous epithelial ovarian cancer (HGSOC), which is hypothesized to originate from serous tubal intraepithelial lesions in the fallopian tubes rather than the ovarian epithelium ([@b2-ol-0-0-5969]). Less frequently observed are endometrial and clear cell carcinomas, associated with endometrial cells, while mucinous carcinomas are associated with gastrointestinal tract tissue. Molecular changes in the genes encoding tumor protein p53, breast cancer type 1 susceptibility protein (BRCA1), BRCA2, GTPase Kras and proto-oncogene B-Raf are known to be fundamental for the development of different subtypes of EOC. The results of epidemiological studies have also revealed that reproductive factors, which determine the exposure of females to steroid hormones, particularly estrogens, serve a role in the development of all subtypes of EOC, although their contribution varies between subtypes ([@b3-ol-0-0-5969]--[@b5-ol-0-0-5969]). While the application of hormonal contraceptives and a higher number of pregnancies reduce the risk for all ovarian cancer types, estrogen-only hormone replacement therapy (HRT) was found to increase the risk for serous and endometrioid EOCs. A higher overall lifetime exposure to estrogens through an early menarche and late menopause was demonstrated to be associated with an increased risk of non-serous ovarian cancers but it may not increase the incidence of HGSOC ([@b6-ol-0-0-5969]--[@b10-ol-0-0-5969]).

When investigating the effect of estrogens on EOC cells, it is of note that these tumors occur predominately in postmenopausal women, at a time when the *de novo* synthesis of the most active form of estrogen, 17β-estradiol (E2), in the ovary has ceased. However, cells in the ovary and other estrogen-sensitive tissues, such as the endometrium and breast, remain exposed to E2 provided from circulating estrogen precursors, particularly estrone sulfate (E1S), taken up from the circulation via specific transport proteins, including members of the organic anion transporting polypeptide family ([Fig. 1](#f1-ol-0-0-5969){ref-type="fig"}) ([@b11-ol-0-0-5969]). A study by Sasano *et al* ([@b12-ol-0-0-5969]) demonstrated that in postmenopausal women, the local concentration of estrogen in breast and endometrial carcinoma are of a similar level compared with those in premenopausal women. This local estrogen production has been demonstrated to be important for the progression of hormone-dependent cancer of the breast and endometrium ([@b13-ol-0-0-5969]--[@b15-ol-0-0-5969]).

In breast cancer cells, the local production of E2 from E1S via the sulfatase pathway has been revealed to exceed the production of E2 from androgenic precursors, including dehydroepiandrosterone sulfate (DHEA-S) via the aromatase pathway ([@b16-ol-0-0-5969]). In the sulfatase pathway, subsequent to the cellular uptake of E1S, which is the most abundant type of estrogen in the circulation of postmenopausal women ([@b17-ol-0-0-5969]), estrone (E1) that has weak estrogenic activity is formed by the enzymatic activity of the steroid sulfatase (STS; [Fig. 1](#f1-ol-0-0-5969){ref-type="fig"}). Subsequently, E2 is produced from E1 by the activity of 17β-oxoreductase. Conversely, E2 may be reverted back to E1 via the oxidative function of 17β-hydroxysteroid dehydrogenase. As an inactivation pathway, E2 conjugation with sulfonate by estrogen sulfotransferase (SULT1E1) and phenol sulfotransferase (SULT1A1) produces estradiol sulfate (E2S), which exhibits minimal estrogenic activity. Conversely, STS may produce active estrogens from E2S and E1S, suggesting that an increase in the level of STS raises the levels of active estrogens and contributes to the progression of estrogen-sensitive types of cancer. Increased expression of STS has previously been identified to be associated with breast cancer progression ([@b18-ol-0-0-5969]). Similarly, in a small group of patients with advanced stage ovarian cancer an increased level of STS activity was revealed to be associated with a worse progression-free survival (PFS) ([@b19-ol-0-0-5969]). Additionally, STS mRNA was detectable in ovarian cancer cells, with similar levels detected in tissue from pre- and postmenopausal women ([@b20-ol-0-0-5969]), but was not detectable in normal ovarian surface epithelial cells ([@b14-ol-0-0-5969]).

Exerting the opposite effect to STS, the increased expression of estrogen-inactivating sulfotransferases may have beneficial effects in malignant and non-malignant diseases known to be sensitive to estrogens. For example, in ovarian endometriosis the expression of SULT1E1, but not of SULT1A1, was demonstrated to be decreased compared with normal tissue ([@b20-ol-0-0-5969]), suggesting that SULT1E1 is important for estrogen inactivation. The importance of SULT1E1 expression was also revealed in breast cancer, where increased levels of the enzyme are associated with a decreased risk of recurrence and an improved prognosis ([@b12-ol-0-0-5969]). Similarly, the overexpression of SULT1E1 was identified to reduce the growth of hormone-sensitive breast cancer cells and block tumorigenesis in a xenograft cancer model ([@b21-ol-0-0-5969]). In endometrial cancer, higher levels of STS compared with SULT1E1 were correlated with a poorer prognosis ([@b22-ol-0-0-5969]). For ovarian cancer, no studies regarding SULT1E1 are available at present, to the best of our knowledge.

The effects of estrogen on cell differentiation and proliferation are largely mediated via the binding and activation of nuclear estrogen receptor (ER) α and ERβ. Numerous studies have revealed that in estrogen-sensitive tumors, including breast and endometrium carcinoma, ERs and estrogen activation via the sulfatase pathway serve a crucial role in tumor progression ([@b23-ol-0-0-5969],[@b24-ol-0-0-5969]). Similarly, in preclinical models of ovarian cancer, a high expression of ERα was identified to promote tumor progression and the development of metastasis by inducing epithelial-mesenchymal transition. In ovarian cancer patients, ERα was demonstrated to be important for tumor progression and a potential target for endocrine therapy of EOC ([@b25-ol-0-0-5969],[@b26-ol-0-0-5969]). However, the success of endocrine therapy targeting ERα remains limited, although the vast majority of EOC subtypes, particularly HGSOC and endometrioid tumors, were found to express the receptor ([@b27-ol-0-0-5969]). Therefore, hormonal treatment selection based on ER, SULT1E1 and STS expression may lead to an improved patient outcome.

The present study aimed to examine the expression of STS, SULT1E1 and ERα protein in a well-defined cohort of patients with advanced EOC. Additionally, the prognostic value of these targets was determined in patients with HGSOC histology, being the most frequently observed and lethal subtype of ovarian cancer.

Materials and methods
=====================

### Patients

The levels of STS, SULT1E1 and ERα protein were examined in paraffin-embedded tumor sections from 206 patients with EOC. Samples were collected as part of the European Union-funded specific targeted research project 'Ovarian Cancer: Diagnosis of a silent killer'. Patients with FIGO stage II--IV ovarian cancer were included from December 2005 to November 2008 in The Department of Gynecology at Charité, Medical University Berlin, Germany; The Department of Obstetrics and Gynecology and Gynecologic Oncology, University Hospital Leuven, Belgium: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; The Department of Obstetrics and Gynecology, Medical University of Vienna, Austria. Patients with other malignancies were excluded. Informed consents were obtained from all patients. The study protocol was approved by the Ethics Committees of the participating institutions (approval nos. EK207/2003: Berlin; ML2524: Leuven; HEK190504: Hamburg; EK366 and EK260: Vienna), with the permission to characterize new molecular prognostic factors for patients with advanced EOC.

Only patients with Federation of Gynecology and Obstetrics (FIGO) stage II--IV ([@b27-ol-0-0-5969]) EOC receiving standard treatment, debulking surgery and platinum-based chemotherapy with taxol derivatives were included in the present study. Patients presenting with benign ovarian diseases, low malignant potential ovarian cancer, FIGO stage I EOC and secondary malignant diseases were excluded. All patients provided preoperative written informed consent prior to enrollment in the present study. Histopathological grading was done for all tumors, grade 1-grade 3, according to tissue differentiation ([@b28-ol-0-0-5969]).

PFS was defined as the time interval between the date of primary surgery and the date of first progression or recurrence of cancer. Disease progression subsequent to first-line chemotherapy was diagnosed by clinical examination, tumor imaging or by a \>2-fold increase in the nadir serum cancer antigen-125 level. Overall survival (OS) was defined as the time interval between initial cytoreductive surgery, EOC-associated mortality or last follow-up. Clinical and histopathological evaluation was performed under the supervision of experienced gynecologic oncologists and pathologists in the participating institutions of the present study.

### Immunohistochemical (IHC) staining

IHC staining was performed on tissue microarrays (TMAs) containing 2 core sections/tumor tissue (1 mm diameter). Subsequent to heating the sections in a tissue-drying oven for 1 h at 60°C, antigen retrieval was performed for 10 min with DEPP-buffer (pH 9.0; Eubio, Vienna, Austria) in a microwave. Blocking for endogenous peroxidase and applying the Lab Vision™ Ultra V Block (UltraVision LP Detection System; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The UltraVision LP Detection System was used according to the manufacturer\'s instructions. Incubation with antibodies directed against STS (cat. no. N1C3; dilution, 1:400; GeneTex, Inc., Irvine, CA, USA) and SULT1E1 (cat. no. 12522-1-AP; dilution, 1:200; ProteinTech Group, Inc., Chicago, IL, USA) was performed overnight at 4°C. Antigen retrieval and staining for ERα using mouse IgG1κ directed against recombinant ERα protein (clone 1D5; cat. no. MA5-13191; Thermo Fisher Scientific, Inc.) was performed as previously described by Aust *et al* ([@b29-ol-0-0-5969]). Sections were treated with HRP Polymer prior to the application of a DAB Plus Chromogen/DAB Plus Substrate mixture (ratio, 1:40) (both UltraVision LP Detection System; Thermo Fisher Scientific, Inc.). The nuclei were counterstained with hematoxylin and the slides were then embedded in Fluoromount (SouthernBiotech, Birmingham, AL, US).

### Evaluation of IHC staining results

Images of the TMAs were acquired with the automated quantitative microscopy-based image analysis system TissueFAXS PLUS (TissueGnostics GmbH, Vienna, Austria) using the 20X objective. A minimum of 3 regions of interest were manually drawn in the tumor areas based on the individual tissue structures and data were acquired for these regions. HistoQuest software (version 3.0.3.0161; TissueGnostics GmbH) was used to determine the staining intensity as gray values of between 0 and 250 arbitrary units. Gray values were determined from the minimum (set to 0) to maximum (set to 250) of the average optical density of the DAB stained target using the HistoQuest software. In the histochemical analysis color shades are picked manually in an automated color separation produces to give a gray value channel image for each marker ([@b30-ol-0-0-5969]).

The proportional expression, defined as the percentage of positively stained tumor cells, was used for the calculation of the, mean of mean intensity as described previously ([@b31-ol-0-0-5969]). Staining intensity in the cytoplasm (STS and SULT1E1) or in the nucleus (ERα) was assessed subsequent to setting a cut-off associated with values from negative control images generated by the application of non-immunogenic IgG or phosphate-buffered saline instead of the first antibody. To correct for false positive events, a specific gate according to cell size and intensity staining was defined and applied homogenously to all analyzed samples. For the assessment of data, only samples with a sufficient tissue quality, including structural integrity of the tissue and clear staining quality with an appropriate negative control, were chosen for quantitative microscopic analysis. All procedures were guided, monitored and approved by a pathologist.

### Statistical analysis

Statistical analysis was performed using SPSS software (version 19.0; IBM SPSS, Armonk, NY, USA). Descriptive statistics such as the mean, median, frequency and percentage were used to summarize the data. Data was log-transformed to reach a normal distribution, as appropriate. The abundance values of STS, SULT1E1 and ERα were grouped into high and low abundance groups using the median as cut-off. Statistical correlations between low and high abundance groups and clinicopathological parameters were assessed by the χ^2^ test, Fisher\'s exact test and unpaired t-tests, as appropriate. To assess the impact of STS, SULT1E1 and ERα on PFS and OS, linear log-transformed values were used in univariate and multivariate Cox regression analyses. Multivariate analyses were performed using stepwise regression (backward elimination). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### EOC tumors

The clinicopathological characteristics of the 206 patients with EOC are illustrated in [Table I](#tI-ol-0-0-5969){ref-type="table"}. The median observation period was 68 months (range, 1--96 months). The median age of patients at the time of cytoreductive surgery was 56 years (range, 26--85 years), whereby the macroscopic cytoreduction rate was 70%. Additional clinicopathological characteristics of this cohort have previously been described ([@b32-ol-0-0-5969]).

Representative images of STS, SULT1E1 and ERα staining compared with the negative controls are illustrated in [Fig. 2](#f2-ol-0-0-5969){ref-type="fig"}. Cytoplasmic staining in the tumor cells was visible for STS and SULT1E1. Staining of cells in the tumor stroma was weak and infrequent in immune cells. Immunoreactive ERα staining was observed in the tumor cell nuclei and, occasionally, in the perinuclear region.

For the evaluation of the abundance of STS, SULT1E1 and ERα, only tissue samples fulfilling the requirements for a quantitative microscopy-based image analysis, aforementioned in the methods section, were included in the present study. The mean levels of immunoreactive STS, SULT1E1 and ERα were calculated and patients were stratified into high and low target abundance groups ([Table I](#tI-ol-0-0-5969){ref-type="table"}). Finally, tumor tissue samples from 206, 200 and 202 patients were evaluated for SULT1E1, STS and ERα abundance, respectively. No significant differences regarding clinicopathological characteristics (tumor histology, age, FIGO stage and residual tumor) were observed between the low and high ERα and STS abundance groups. However, the degree of tissue differentiation ([@b28-ol-0-0-5969]) was important for the expression level as a significantly higher SULT1E1 abundance was observed in more differentiated grade 1/2 tumors compared with less differentiated grade 3 tumors (P=0.001). A total of 59% of the collective of grade 1/2 compared with 45% grade 3 tumors exhibited high STS abundance (P=0.081). In addition, STS and SULT1E1 protein levels were positively correlated with each other (P\<0.001) and with ERα (P\<0.001 and P=0.001, respectively; data not shown).

### HGSOC

Different histological subtypes of EOC have distinctive characteristics regarding the origin of the tumor, the growth pattern, the sensitivity to chemotherapy and the prognosis. As it is recommended to perform survival analyses for different ovarian cancer subtypes separately ([@b33-ol-0-0-5969]), a homogenous group of patients with a long observation period were used for survival analyses. The data of 137 patients with HGSOC were used to assess the impact of SULT1E1, STS, and ERα abundance on clinical outcome ([Table II](#tII-ol-0-0-5969){ref-type="table"}). During the median observation period of 68 months (range, 1--96 months), a total of 84 (64%) patients succumbed to the disease and 113 (86%) patients experienced a tumor recurrence (data not shown).

Multivariate Cox regression analysis revealed that SULT1E1 abundance was a significant independent predictor for OS (hazard ratio, 0.66; 95% confidence interval, 0.45--0.94; P=0.005; [Table II](#tII-ol-0-0-5969){ref-type="table"}). Notably, neither ERα nor STS abundance exhibited a significant impact on OS. These results suggest that patients with higher SULT1E1 levels have a better prognosis, independent from the most relevant confounding parameters demonstrated in [Table II](#tII-ol-0-0-5969){ref-type="table"}. The abundance of ERα, STS and SULT1E1 were not significantly associated with PFS ([Table II](#tII-ol-0-0-5969){ref-type="table"}).

### Non-serous tumors

STS, SULT1E1 and ERα were also detected in non-serous tumors ([Table I](#tI-ol-0-0-5969){ref-type="table"}). Due to the limited number of patients (n=21; endometrioid tumors, n=11; clear cell tumors, n=2; mixed epithelial tumors, n=7; mucinous tumors, n=1) and the heterogeneity of the tumors, distinct survival analyses were not performed for the non-serous tumor group.

Discussion
==========

The intratumoral production of E2 from circulating E1S via the sulfatase pathway, including the enzymes STS for estrogen activation and SULT1E1 for estrogen inactivation, serves an important role in estrogen-associated cancer of the breast and endometrium ([@b34-ol-0-0-5969]). Therefore, the present study determined the levels of STS, SULT1E1 and ERα in a well-defined cohort of 205 EOC patients. This revealed that SULT1E1 abundance exhibited a significant independent prognostic value for OS in 137 patients with HGSOC treated with debulking surgery and standard platinum-based adjuvant chemotherapy. A high level of SULT1E1 was associated with a longer OS in patients with HGSOC, which is concordant with results from previous studies of breast and endometrial cancer. In these tumors, high SULT1E1 levels were found to be associated with a better prognosis for patients, as demonstrated by a decreased risk of recurrence and an increased OS ([@b13-ol-0-0-5969],[@b22-ol-0-0-5969]). This beneficial role of SULT1E1 is further supported by the finding that SULT1E1 is typically downregulated in malignant tissue ([@b34-ol-0-0-5969],[@b35-ol-0-0-5969]). In addition, preclinical studies have demonstrated that the inactivation of E2 by sulfonation reduces the proliferative effects of estrogens on hormone-sensitive tumor cells ([@b36-ol-0-0-5969]). Furthermore, the conjugation of estrogens by SULT1E1 creates water-soluble estrogen sulfates, which may be rapidly excreted from the cells. Effective sulfonation and rapid excretion of the sulfonated E2 may prevent the metabolic activation of the hormone into potential mutagenic catechol metabolites, which increase the mutation rate of DNA and lead to chromosomal instability ([@b37-ol-0-0-5969],[@b38-ol-0-0-5969]). Since the present study did not identify a significant association between STS and OS/PFS, in HGSOC SULT1E1 may be of a higher relevance compared with STS for estrogen inactivation and estrogen homeostasis. However, Chura *et al* ([@b19-ol-0-0-5969]) reported that a decreased level of STS activity was associated with a higher OS, based on a smaller cohort of patients with ovarian cancer (n=37) with no additional characterization of the tumor subtypes. Therefore, the clinicopathological characteristics and number of patients included in the present study may explain the diverging data in regards to STS, particularly as a large number of patients with HGSOC were included. However, data on the association between STS expression and tumor progression remain controversial even in otherwise well-studied endometrial carcinomas. This may be partly explained by different approaches to investigating estrogen-modifying enzymes. For example, Abulafia *et al* ([@b39-ol-0-0-5969]) identified that there was higher STS activity in endometrial carcinoma compared with normal endometrial tissues using DHEA-sulfate as a substrate, but Tanaka *et al* ([@b40-ol-0-0-5969]) reported a decreased level of STS activity in endometrial carcinoma compared with normal endometrium as the lining of the uterus and endometrial adenocarcinoma-derived cells using E1S as a substrate.

Despite the uncertainty with respect to the role of STS in the progression of gynecological cancers and the limited data from clinical trials, STS has been proposed to be a potential hormonal therapeutic target for the treatment of estrogen-associated cancer ([@b41-ol-0-0-5969]). It must be considered that the regulation of STS expression is subject to various feedback mechanisms, including the levels of active estrogens ([@b42-ol-0-0-5969]). Therefore, in EOC the increased inactivation of E2 by low levels of SULT1E1 may cause an upregulation of STS. Indeed, a significant association between the expression of SULT1E1/STS and ERα was identified in the present study, similarly to the results of a previous study investigating breast cancer ([@b43-ol-0-0-5969]). In the present study, although STS and SULT1E1 abundance was significantly associated and the abundance of these enzymes was significantly associated with the level of ERα, the receptor itself exhibited no significant impact on PFS or OS. In a study with a large cohort of patients with serous EOC, the expression levels of ERα and ERβ did not provide any prognostic information ([@b14-ol-0-0-5969],[@b44-ol-0-0-5969]).

From the data obtained, the present study concludes that targeting estrogen-modifying enzymes in the sulfatation pathway is a potential strategy for the endocrine therapy of estrogen-sensitive ovarian cancer. Targeting the sulfatase pathway was previously suggested as an endocrine therapy option for breast cancer ([@b45-ol-0-0-5969]). In a mouse xenograft model, blocking aromatase together with the application of the STS inhibitor STX64 reduced the estrogen level in tumors ([@b46-ol-0-0-5969]). This is important as the application of the estrogen-depleting aromatase inhibitor exemestane can cause an upregulation of intratumoral STS, leading to therapy resistance ([@b47-ol-0-0-5969]). Whether SULT1E1 may also be downregulated through feedback mechanisms remains unknown. However, STX64 was found to inhibit the growth of the ER^+^ ovarian carcinoma OVCAR-3 cell line and thus may be considered a target for ovarian cancer therapy ([@b48-ol-0-0-5969]). The importance of SULT1E1 was also identified in the use of the prodrug tibolone, which improves bone structure in postmenopausal women as it is metabolized into 2 products with antagonistic effects on ERα. In the endometrium, SULT1E1 effectively converts these 2 metabolic products to inactive sulfate conjugates, preventing ERα activation and reducing the risk of endometrial cancer induction ([@b49-ol-0-0-5969]).

In conclusion, the results of the present study suggest that estrogen-modifying enzymes in the sulfatase pathway, such as STS and SULT1E1, are potential endocrine therapy targets for the treatment of patients with EOC.

The present study was supported by the European Union-funded Sixth Framework Programme Specific Targeted Research Project Ovarian Cancer: Diagnosis of a silent killer (grant no. 018698).

![Intratumoral synthesis of E2 and its inactivation by sulfate conjugation from circulating steroid hormone precursors in cancer cells. E2 is synthesized from E1S in the sulfatase pathway, and from DHEA-S in the aromatase pathway. E1S and DHEA-S are taken up from the circulation by transporters, such as those from the OATP family encoded by *SCLO*. In the sulfatase pathway, HSD-17β1 generates E2 from E1S, while E1 and E2 are inactivated by sulfonation by SULT1E1. Sulfonated estrogens do not bind to the ERα or ERβ. Aromatase generates E2 from androgenic precursors via the aromatase pathway. E2, 17β-estradiol; -S, sulfate; E1, estrone; STS, steroid sulfatase; SULT1E1, estrogen sulfotransferase; ER, estrogen receptor; DHEA, dehydroepiandrosterone sulfate; HSD-17β, 17β-hydroxysteroid dehydrogenase; OATP, organic anion transporting polypeptides; SLCO, solute carrier for organic anions.](ol-13-06-4047-g00){#f1-ol-0-0-5969}

![Representative images of immunohistochemical staining for (A) STS, (B) SULT1E1 and (C) ERα subsequent in paraffin-embedded sections from serous epithelial ovarian cancer. Cytoplasmic staining was observed for STS and SULT1E1, while ERα staining was predominantly observed in the nucleus. Respective images from negative control samples for (D) STS, (E) SULT1E1 and (F) ERα. Magnification, ×200. STS, steroid sulfatase; SULT1E1, estrogen sulfotransferase; ERα, estrogen receptor α.](ol-13-06-4047-g01){#f2-ol-0-0-5969}

###### 

Epithelial ovarian cancer study population divided into high and low ERα, STS and SULT1E1 abundance groups using the median as cut-off.

  Clinicopathological characteristic                                   ERα low (n=106), no. of patients (%)   ERα high (n=96), no. of patients (%)   P-value                                              STS low (n=104), no. of patients (%)   STS high (n=96), no. of patients (%)   P-value                                              SULT1E1 low (n=98), no. of patients (%)   SULT1E1 high (n=108), no. of patients (%)   P-value
  -------------------------------------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------------------------- ----------------------------------------- ------------------------------------------- ----------------------------------------------------
  Age (years)                                                                                                                                                                                                                                                                                                                                                                                                                      
    \<55                                                               55 (60)                                37 (40)                                                                                     50 (48)                                37 (39)                                                                                     44 (48)                                   47 (52)                                     
    ≥55                                                                51 (46)                                59 (54)                                0.057                                                54 (48)                                59 (52)                                0.174                                                54 (47)                                   61 (56)                                     0.842^[c](#tfn4-ol-0-0-5969){ref-type="table-fn"}^
  Histology                                                                                                                                                                                                                                                                                                                                                                                                                        
    Serous                                                             95 (52)                                88 (48)                                                                                     94 (52)                                87 (48)                                                                                     88 (48)                                   97 (52)                                     
    Non-serous^[a](#tfn2-ol-0-0-5969){ref-type="table-fn"}^            11 (58)                                  8 (42)                               0.619                                                10 (52)                                  9 (48)                               0.954                                                10 (48)                                   11 (52)                                     0.996
  FIGO stage                                                                                                                                                                                                                                                                                                                                                                                                                       
    II                                                                   3 (43)                                 4 (57)                                                                                      4 (57)                                 3 (43)                                                                                      5 (71)                                    2 (29)                                    
    III                                                                86 (53)                                76 (47)                                                                                     82 (52)                                77 (48)                                                                                     74 (45)                                   89 (55)                                     
    IV                                                                 17 (51)                                16 (49)                                0.914^[c](#tfn4-ol-0-0-5969){ref-type="table-fn"}^   18 (53)                                16 (47)                                1.000^[c](#tfn4-ol-0-0-5969){ref-type="table-fn"}^   19 (53)                                   17 (47)                                     0.329^[d](#tfn5-ol-0-0-5969){ref-type="table-fn"}^
  Grade^[b](#tfn3-ol-0-0-5969){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                                                                                                               
    Grade 1/2                                                          24 (44)                                31 (56)                                                                                     22 (42)                                31 (59)                                                                                     15 (28)                                   38 (72)                                     
    Grade 3                                                            82 (56)                                64 (44)                                0.113                                                81 (56)                                65 (45)                                0.081                                                83 (54)                                   69 (46)                                     0.001
  Residual tumor status^[b](#tfn3-ol-0-0-5969){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                                                                                               
    Absent                                                             73 (51)                                69 (49)                                                                                     66 (48)                                72 (53)                                                                                     66 (46)                                   78 (54)                                     
    Present                                                            33 (55)                                27 (45)                                0.640                                                38 (61)                                24 (39)                                0.078                                                32 (52)                                   30 (48)                                     0.446

Age: Since the average age for menopause ranges between 47 and 55 years, all EOC patients \>55 years were considered postmenopausal (50).

Histology; SULT1E1 was evaluated in 206 samples; 21 non-serous tumor samples: endometrioid tumors, n=11; clear cell tumors, n=2, mixed epithelial tumors, n=7, mucinous tumors, n=1. Note that for ERα and STS evaluation, only 200 and 202 samples were appropriate and data from 19 non-serous tumor are given; 1 endometroid and 1 mixed epithelial tumor are missing (27).

1 case missing.

Unpaired *t*-test

Fisher\'s exact test, other P-values were calculated by the χ^2^ test. EOC, epithelial ovarian cancer; STS, steroid sulfatase; SULT1E1, estrogen sulfotransferase; ERα, estrogen receptor α; FIGO, Federation of Gynecology and Obstetrics.

###### 

Univariate and multivariate Cox regression analyses (backward conditional) for progression-free survival and overall survival of patients with high grade serous ovarian carcinoma (HGSOC) with FIGO III/IV tumors (n=132).

                                                                                  Progression-free survival   Overall survival                                                                                   
  ------------------------------------------------------------------------------- --------------------------- ------------------ ------------------- --------- ------------------- --------- ------------------- ---------
  Age (continuous, per decade)                                                    1.18 (0.99--1.99)           0.053              1.20 (1.01--1.01)   0.040     1.39 (1.14--1.14)   \<0.001   1.51 (1.22--1.22)   \<0.001
  FIGO stage (ordinal, III vs. IV)                                                2.91 (1.86--4.86)           \<0.001            2.87 (1.78--4.78)   \<0.001   2.3 (1.43--3.43)    0.001     2.07 (1.24--3.24)   0.005
  Residual tumor (absent vs. present)                                             1.48 (0.99--2.99)           0.053              --                            2.14 (1.38--3.38)   0.001     1.96 (1.23--3.23)   0.005
  ERα abundance (high vs. low)^[a](#tfn7-ol-0-0-5969){ref-type="table-fn"}^       1.01 (0.81--1.81)           0.903              --                            0.21 (0.67--1.67)   0.206     --                  
  STS abundance (high vs. low)^[a](#tfn7-ol-0-0-5969){ref-type="table-fn"}^       0.98 (0.71--1.71)           0.926              --                            0.93 (0.65--1.65)   0.720     --                  
  SULT1E1 abundance (high vs. low)^[a](#tfn7-ol-0-0-5969){ref-type="table-fn"}^   1.08 (0.76--1.76)           0.676              --                            0.78 (0.79--1.79)   0.154     0.66 (0.45--0.45)   0.005

The age of the patients with HGSC ranged between 27 and 83 years. The hazard ratio increased with age per decade (10-year steps).

STS, SULT1E1 and ERα levels were grouped into high and low abundance groups using the median as cut-off level. Univariate and multivariate Cox regression analyses (backward conditional) were performed to assess enzyme and receptor high and low abundance as determinants associated with progression-free and overall survival. FIGO, Federation of Gynecology and Obstetrics; STS, steroid sulfatase; SULT1E1, estrogen sulfotransferase; ERα, estrogen receptor α; HR, hazard ratio; CI, confidence interval.
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